+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ANUHPHR

Anuh Pharma Share Price

 

 

Anuh Pharma live price: ₹78.9. It opened at ₹80 vs previous close ₹80; intraday high/low: ₹82/₹78. The 50 & 200 DMA stand at ₹78.15/₹81.12.

Anuh Pharma Performance

  • Today's Low
  • ₹78
  • Today's High
  • ₹82
  • 52 Week Low
  • ₹67
  • 52 Week High
  • ₹115
  • Open Price₹80
  • Previous Close₹80
  • Volume46,023
  • 50 DMA₹78.15
  • 100 DMA₹78.60
  • 200 DMA₹81.12

Anuh Pharma Chart

Investment Returns

  • Over 1 Month + 0.39%
  • Over 3 Month + 4.31%
  • Over 6 Month + 1.83%
  • Over 1 Year -25.43%

Smart Investing Starts Here Start SIP with Anuh Pharma for Steady Growth!

Invest Now

Anuh Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 19.3
  • PEG Ratio
  • -1.4
  • Market Cap Cr
  • 791
  • P/B Ratio
  • 2.2
  • Average True Range
  • 3.23
  • EPS
  • 4.1
  • Dividend Yield
  • 1.9
  • MACD Signal
  • -0.37
  • RSI
  • 52.46
  • MFI
  • 73.24

Latest Stock News Updates

Anuh Pharma up 7% on receiving WHO prequalification for anti-malarial API

The buying on the counter came after the company received World Health Organization (WHO) prequalification approval for Amodiaquine Hydrochloride USP

Anuh Pharma Financials

Anuh Pharma Technicals

EMA & SMA

Current Price
₹78.90
-0.89 (-1.12%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹78.00
  • 50 Day
  • ₹78.20
  • 100 Day
  • ₹78.60
  • 200 Day
  • ₹81.10

Resistance and Support

79.7 Pivot Speed
  • R3 84.70
  • R2 83.30
  • R1 81.10
  • S1 77.50
  • S2 76.10
  • S3 73.90

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anuh Pharma has an operating revenue of Rs. 771.66 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 7% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its key moving averages, around 0% and 0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 63 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anuh Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-20 Audited Results, Final Dividend & A.G.M.
2026-02-06 Quarterly Results
2025-11-07 Quarterly Results
2025-08-08 Quarterly Results & Others To consider other business matters. per share(30%)Final Dividend
2025-05-23 Audited Results, Dividend & Bonus issue
Date Purpose Remarks
2025-08-15 FINAL Rs.1.50 per share(30%)Final Dividend (RD date revised)
View Anuh Pharma Dividend History Arrow
Date Purpose Remarks
2025-07-15 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 5/-

Anuh Pharma Shareholding Pattern

71.8%
0%
0.05%
0%
23.56%
4.59%

Anuh Pharma FAQs

Anuh Pharma share price is ₹78 As on 19 June, 2026 | 05:35

The Market Cap of Anuh Pharma is ₹790.8 Cr As on 19 June, 2026 | 05:35

The P/E ratio of Anuh Pharma is 19.3 As on 19 June, 2026 | 05:35

The PB ratio of Anuh Pharma is 2.2 As on 19 June, 2026 | 05:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23